Eupraxia Pharmaceuticals (NASDAQ:EPRX) Upgraded at RODMAN&RENSHAW

RODMAN&RENSHAW upgraded shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) to a strong-buy rating in a research note issued to investors on Thursday,Zacks.com reports.

Separately, Rodman & Renshaw initiated coverage on shares of Eupraxia Pharmaceuticals in a report on Thursday. They set a “buy” rating and a $9.00 target price on the stock.

Eupraxia Pharmaceuticals Stock Performance

Shares of NASDAQ EPRX traded up $0.10 during mid-day trading on Thursday, hitting $3.00. The stock had a trading volume of 4,345 shares, compared to its average volume of 15,321. Eupraxia Pharmaceuticals has a 1 year low of $2.20 and a 1 year high of $5.58. The business has a 50 day moving average price of $2.66 and a two-hundred day moving average price of $2.68. The firm has a market cap of $81.84 million and a P/E ratio of -4.08.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

A hedge fund recently bought a new stake in Eupraxia Pharmaceuticals stock. 180 Wealth Advisors LLC bought a new position in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 13,000 shares of the company’s stock, valued at approximately $34,000.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.